Sutro Biopharma Announces Update from STRO-002

Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer

Events, News, Presentations, Press Releases

Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer – Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected...